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We examined mice with cardiac specific deletion of the gene encoding glucose 
transporter 4 (GLUT4, G4H
-/-
). These mice develop moderate cardiac hypertrophy with 
normal basal cardiac function and show signs of mitochondrial and whole cell oxidative 
stress as evidenced by increased concentration of oxidized glutathione (GSSG). 
Preliminary research in our laboratory has shown that treatment with the antioxidant 
tempol (a whole cell antioxidant), but not MnTBAP (a mitochondrial targeted superoxide 
2 mimetic), can attenuate cardiac hypertrophy. Furthermore, GSSG concentrations were 
not altered by tempol, but reduced by MnTBAP. Based on these preliminary data, we 
hypothesized that 1) glutathione peroxidase (Gpx) was elevated and glutathione reductase 
(Gsr) was lower in hearts of G4H
-/-
 mice. Both Gpx and Gsr are important components of 
glutathione cycle. 2) MnTBAP treatment increases Gsr and lowers Gpx expression, but 
tempol did not affect either of them. 3) Tempol treatment can decrease GSK3 
phosphorylation and increase Txn2 expression. 
In contrast to our hypothesis, Gpx was not elevated in G4H
-/-
 mice and Gsr levels 
were similar between G4H
-/-
 and control.  Treatment with either tempol or MnTBAP did 
 iv 
 
not affect Gpx protein levels. On the other hand, tempol reduced Gsr in G4H
-/-
 mice vs. 
untreated G4H
-/-
 and controls. GSK3β activity was similar between G4H-/- mice and  
controls and remained unchanged after tempol and MnTBAP. Txn2 expression was also 
similar between controls and G4H
-/-
. Tempol treatment increased Txn2 mRNA 
expression in controls only, but MnTBAP did not affect Txn2 in any group. Additionally, 
after tempol treatment, mRNA level of Gpx was not elevated in G4H
-/-
 mice but actually 
lower, whereas Gsr was unchanged.  
To sum up, the reduction of hypertrophy after tempol treatment was not associated 
with changes in; a) GSK3β  phosphorylation, b) enzymes used in the glutathione 
oxidation and reduction cycle, or c) Txn2 expression. Additionally, though preliminary 
studies found a reduction of GSSG after MnTBAP treatment, the present study found this 
was not accompanied by any change in Gpx or Gsr. Therefore, we conclude that the 
attenuation of cardiac hypertrophy is unrelated to the modulation of oxidative stress by 
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From the most recent report of American Heart Association some 500,000 people 
have hypertrophic cardiomyopathy, yet most are unaware of it.
 [1]
 Hypertrophy can be a 
normal response to cardiovascular conditioning associated with exercise or pregnancy. 
This type of hypertrophy is classified as ‘physiological’, [2] and is distinguishable by its 
reversibility. In contrast, pathological cardiac hypertrophy is caused by the ventricle 
adapting to disease-inducing stimuli, such as chronically increased volume load (preload) 
or increased pressure load (afterload). Although it is an adaptation to the stress, 
prolonged stress-induced hypertrophy can lead the fibrosis and cardiac dilation, which is 
generally associated with symptoms of heart failure. 
[3]
 
Some data suggests that cardiovascular disease (CVD) risk appears to associate with 
the duration of diabetes mellitus (DM), with the rapidly rising global incidence of DM, 
and CVD is the major cause of morbidity and mortality in patients with diabetes. 
[4] 
Insulin resistance typically precedes the onset of type 2 diabetes and is accompanied by 
other cardiovascular risk factors, including dyslipidemia, hypertension, and 
prothrombotic factors.
 [5, 6]
 which commonly precede the development of type 2 diabetes 
by many years; 
[7] 





risk. Moreover, epidemiological and clinical studies report that diabetes can lead to 
cardiac hypertrophy independent from coronary artery disease, ischemia, or hypertension, 
[8-10] 
for reasons that are still unclear. 
One possible explanation for hypertrophy in the prediabetic insulin-resistant heart is 
oxidative stress. Reactive oxygen species (ROS), which are a commonly reported feature 
in the diabetic heart, 
[11-13] 
have emerged as key mediators in cardiac pathophysiology.
 
[14-20]
 Initially, insulin resistance is compensated by hyperinsulinemia through which a 
normal glucose tolerance is preserved. Deterioration to impaired glucose tolerance occurs 
when insulin resistance increases further and/or the compensatory insulin secretion 
decreases. An increase in insulin, free fatty acid, and/or glucose levels can increase ROS 
production and oxidative stress, as well as activate stress-sensitive pathways. 
[21] 
Many 
studies support that ROS generated by NADPH oxidase is a vital link in signaling 
pathways that stimulate cardiac hypertrophy. 
[22-31]
 
To study the effects of cardiac specific insulin resistance, a mouse model with 
cardiac specific GLUT4-deletion (G4H
-/-
) was developed by Abel et al. 
[32]
 Different from 
global GLUT4 suppression, G4H
-/-
 mice have reduced glucose uptake without 
interference from pathology stemming from systemic insulin resistance. In addition, 
moderate cardiac hypertrophy, without fibrosis, develops in G4H
-/-
 mice by 8 weeks of 
age in the absence of hyperinsulinemia, hyperglycemia, or changes in serum 
concentrations of fatty acid, lactate, amino acids, or ketones.
 [32]





have normal basal cardiac function,
 [32]




Preliminary work from our laboratory showed oxidative stress in hearts of G4H
-/-
 
mice as evidence by increased whole cell and mitochondrial oxidized glutathione 
concentrations. Interestingly, tempol (a whole cell antioxidant) treatment prevented 
cardiac hypertrophy in G4H
-/-
 mice, but did not improve the ratio of reduced glutathione 
to oxidized glutathione (GSH:GSSG) nor blunt the increased expression of cardiac 
p67
phox
, which is a subunit of NADPH oxidase. In contrast, MnTBAP (mitochondrial 
targeted superoxide 2 mimetic) treatment reduced mitochondrial concentrations of 
oxidized glutathione, but did not reduce cardiac hypertrophy. Therefore, in the present 
study, glutathione peroxidase (Gpx) and glutathione reductase (Gsr), important enzymes 
involved in glutathione cycle, were selected to observe. Gpx can convert hydrogen 
peroxide to water through oxidizing glutathione, and Gsr reduces GSSG to GSH. 
Our preliminary studies using tempol treatment suggest that it is possible that in 
addition to oxidative stress, other mechanisms, independent of oxidative stress, may be 
operative in regulating cardiac hypertrophy in G4H
-/-
 mice. For example, it has been 
proposed that attenuation of diabetic cardiomyopathy by tempol treatment is possibly 
associated to modulation of Glycogen synthase kinase 3β (GSK3β) and thioredoxin (Txn). 
[4, 38]
 Studies have shown that inactivation of GSK3 induces hypertrophic growth of 





also by releasing eIF2B. A number of studies suggest that GSK3α and GSK3, but 
GSK3 in particular, plays a pivotal role in cardiac hypertrophy. [34, 35] It is also possible 
that Txn2, a mitochondrial redox protein, may have played a role in modulation of 
hypertrophy, not only because of its antioxidant property for maintaining the 
mitochondrial redox state and scavenging mitochondrial ROS, but also because of its 
signaling function in modulating Apoptosis signal-regulating kinase 1 and transcription 
factors NF-κB involved in cell growth/apoptosis and inflammation. Studies have shown 
both suppression and overexpression of thioredoxin2 induce hypertrophy. 
[36, 37]
  
Given our preliminary data,
 
we conducted this follow-up study to test three 
hypotheses. 1) Gpx is elevated and Gsr is lower in G4H
-/-
 mice. 2) MnTBAP treatment 
increases Gsr and lowers Gpx expression, but tempol did not affect either of them. 3) 

















II. MATERIALS AND METHODS 
Animals 
Mice with cardiac specific deletion of GLUT4 were generated by crossing mice 
bearing the modified GLUT4 gene containing loxP sites with transgenic mice with 
cardiac-specific expression of the enzyme cre recombinase in the laboratory of Dr. Dale 
Abel, University of Utah. Mice with normal cardiac GLUT4 expression were used as 
control (CON). All animals were housed in E. E. Jones Medical Science Building, 
University of Utah, and kept on a 12 h light/dark cycle, with room temperature 24°C and 
all experiments were conducted on random fed mice. Mixed cohorts of male and female 






All protocols were approved by the University of Utah Institutional Animal Care 
and Use Committee. Mice were given treatment at 4 weeks old, when they start to 
develop cardiac hypertrophy. These mice were separated into two experiments. Each 
experiment contained four groups. In tempol experiment, there were CON (n=8), G4H
-/-
 
(n=7), CON+T (n=9), and G4H
-/-





drinking water supplemented with the antioxidant tempol (4-hydroxy-2,2,6,6- 
tetramethylpiperidine-N-oxyl, 1 mM). Daily fluid consumption was monitored 
throughout the 4-week treatment period. In MnTBAP experiment, there were CON (n=3), 
G4H
-/-
 (n=3), CON+MnTBAP (n=4), and G4H
-/-
+MnTBAP (n=5). Mice were given 200 
µL injections of either saline (0.9%) or MnTBAP [(Mn(III)tetrakis(4-Benzoic acid) 
porphyrin chloride, 10 mg MnTBAP in 10 ml saline, stored in 4°C] every 2 days during 
the 4-week treatment period. At the end of the treatment, mice were anaesthetized (7% 
Chloride Hydrate, 0.1 mL/gram body weight), body weights (BW) recorded and hearts 
were excised and weighed (HW) to determine hypertrophy (HW/BW), and then tibia and 
part of tail excised. Tibia length (TL) was measured to determine hypertrophy (HW/TL). 
Heart samples were snap-frozen in liquid nitrogen and stored at -80°C. 
 
Sample Preparation 
All heart samples were trisected, ensuring that each portion contained a similar 
contribution of left and right ventricles. One tissue piece was homogenized in RIPA 
(RadioImmunoPrecipitation Assay, Tris-HCL, 50 mM, pH 7.4; NP-40, 1%; 
Na-deoxycholate, 0.25%; NaCl, 150 mM; EDTA, 1 mM; Na3VO4, 1:200; NaF, 1:200; 
RIPA, 1:200; Protease inhibitor, 1:200) buffer. Then Bradford assay were conducted to 
detect the protein concentration of each sample. Forty µL dyes and 40 µL 1:100 diluted 





was measured at 595 nm. At last, sample loading buffer was added into each sample to 
bring the final concentration to 2 g / l and stored in 4°C for western blot.  
 
Western Blot 
Glycine–SDS-PAGE (10% separating gel and 4% stacking gel) was used to separate 
proteins. Then gels were transferred to polyvinyl difluoride (PVDF) membrane. After 
blocking with 5% nonfat milk, primary antibodies for detecting protein of Gpx4 
(CAYMAN CHEMICAL, Denver, CO), Gsr (Santa Cruz Biotechnology, Santa Cruz, 
CA), GSK3β, and p-GSK3β (Cell Signaling Technology, Beverly, MA) were incubated 
overnight in 1:1000 diluted with 5% nonfat milk or 5% BSA at 4°C. Secondary 
antibodies conjugated to goat anti-rabbit and anti-biotin (Cell Signaling Technology, 
Beverly, MA) were incubated in 1:5000 dilutions at room temperature for 1 hour. In 
order to avoid false conclusions due to unequal protein loading, we used loading controls 
for all Western blots and normalized target proteins to the density of tubulin 
(SIGMA-ALDRICH, St. Louis, MO). Therefore the errors in protein assay or loading 
were controlled. Signals were visualized by enhanced chemiluminescence (Cell Signaling 
Technology, Beverly, MA). Relative band densities of immunoblots were measured using 








RNA Extraction and RT-PCR 
The following genes were examined using Real Time polymerase chain reaction 
(RT-PCR): Gpx1, Gpx4, Gsr and Txn2. The sequences of primers (5’ to 3’) used for 
RT-PCR were: Gpx1 (forward primer: GACTGGTGGTGCTCGGTT; reverse primer: 
TCACCATTCACTTCGCACTT), Gpx4 (forward primer: GCAGGAGCCAGGAAG 
TAATCAAGA; reverse primer: GCATCGTCCCCATTTACACA), Gsr (forward primer: 
GTGGCACTTGCGTGAATGTTG; reverse primer: GCACTGCTGTGTTCCACATTA 
CCTT) and Txn2 (forward primer: GTGTGGGCTTCCCTCACCTCT; reverse primer: 
GGCTGGGCTGGGCATTACTGTTAGA). Total RNA were extracted from heart 
samples of control and both antioxidant-treated groups using TRIzol reagent (Invitrogen, 
Carlsbad, California) and TissueLyser. Then they were purified using the RNAeasy total 
RNA isolation kit (Qiagen, Valencia, California) and reverse transcribed. Equal amounts 
of cDNA were subjected to real-time PCR using SYBR Green as a probe as previously 
described.
 [39]
 All transcripts were expressed relative to cyclophilin (Cphn), and values 
were normalized to the mean control value.  
 
Statistics 
SPSS for Windows® Graduate Pack (Version 15.0, Chicago, IL) was used to 
analyze the data. Significant difference among groups was compared by one-way analysis 





value was obtained, post hoc test was conducted using Tukey to determine where within 






Index of Cardiac Hypertrophy 
Heart weight was corrected to tibia length to create an index of cardiac hypertrophy. 
Tempol treatment, as compared with vehicle treated group, was associated with a 
significantly lower mean value of index of cardiac hypertrophy, as well as lower absolute 
heart weight (Table 1 and Figure 1). On the other hand, MnTBAP did not significantly 
change heart to tibia length ratios in G4H
-/-
 mice, compared to the vehicle treated G4H
-/-
 
(Table 2 and Figure 2). 
 
Table 1 




   CON G4H-/- CON+T G4H-/-+T 
n n=15 n=13 n=14 n=13 
Heart Weight, mg 110.4±4.2a 143.9±5.7b 111.9±4.8a 121.1±4.8a 
Body Weight, g 20.8±0.8 21.9±1.0 21.0±0.9 19.9±0.9 
Tibia Length, mm 17.2±0.2 17.2±0.1 16.9±0.2 16.8±0.1 












Different letters denote significant difference, p<0.05. 
 











   CON G4H-/- CON+MnTBAP G4H-/-+MnTBAP 
n n=26 n=23 n=30 n=28 
Heart Weight, mg 118.0±3.3 131.0±11.4 120.0±7.9 128.4±10.9 
Body Weight, g 24.2±2.8 21.3±1.3 23.0±1.8 20.4±2.2 
n n=17 n=17 n=19 n=22 
Tibia Length, mm 16.5±0.2 16.6±0.1 16.6±0.1 16.4±0.1 





































Different letters denote significant difference, p<0.05. 
 






Gpx is an antioxidant enzyme known to reduce phospholipid hydroperoxides. In this 
study, vehicle treated G4H
-/-
 mice had greater mRNA, but lower protein level than 
controls (Figure 4 and Figure 5). However, this difference was only in G4H
-/-
 vehicle 
treated mice used in the tempol study, since Gpx4 expression was similar in the G4H
-/-
 
vehicle treated cohort used in the MnTBAP study (Figure 7 and Figure 8). This 
difference may have been related to the smaller sample size used in MnTBAP studies. 
Tempol treatment did not change Gpx4 protein levels in control or G4H
-/-
 mice vs. 








































Figure 3. Western blots of Gpx4, Gsr and ratio of p-GSK3 and GSK3 in mice treated 




All groups are normalized to the mean control value. Different letters denote significant 
difference, p<0.05. 
 
























G4H-/- (n=4)        
 
CON (n=5)         
        
G4H-/-+T (n=4)         
        
CON+T (n=4)         





















All groups are normalized to the mean control value. Different letters denote significant 
difference, p<0.05.  
 
Figure 5. Quantification of Gpx4, Gsr and ratio of p-GSK3 and GSK3 on both 









Figure 6. Western blots of Gpx4, Gsr and ratio of p-GSK and GSK in mice treated with 




































G4H-/- (n=3)        CON (n=3)         















All groups are normalized to the mean control value.  
 




All groups are normalized to mean control value.  
 
Figure 8. Quantification of Gpx4, Gsr and ratio of p-GSK and GSK on both nontreated 

















































 mice compared to vehicle treated G4H
-/-
 (Figure 5). MnTBAP treatment did not 
change Gpx protein or mRNA levels (Figure 7 and Figure 8). 
 
Glutathione Reductase 
Gsr is an important modulator of the glutathione oxidation-reduction cycle. 
Expression of Gsr mRNA and protein levels were similar between all untreated control 
and G4H
-/-
 mice. Tempol treatment reduced Gsr protein levels in G4H
-/- 
mice vs. vehicle 
treated control and G4H
-/-
 mice (Figure 4). MnTBAP did not affect Gsr protein or mRNA 
level in control or G4H
-/-
 mice (Figure 7 and 8). 
 
Glycogen Synthase Kinase 3β Phosphorylation 
Phosphorylation ratio of GSK3 was used to indicate GSK3 activity. Significant 
difference was neither observed in GSK3 phosphorylation between control and G4H-/- 
vehicle treated mice nor among tempol or MnTBAP treated mice (Figure 4 and 7). 
However, sample size for MnTBAP experiment was low and could not be increased due 




Txn2 protein was not detected by Western blot, perhaps due to a lack of antibody 
specificity in mouse heart. G4H
-/-





Tempol treatment increased the expression of Txn2 in control mice but did not alter it in 
G4H
-/-
 mice (Figure 5). MnTBAP treatment did not result in any change in Txn2 mRNA 
level in control or G4H
-/-






In agreement with previous studies using G4H
-/-
 mice, cardiac hypertrophy was 
observed in all untreated G4H
-/-
 mice as evidenced by greater heart weight-to-tibia length 
than control mice. Tempol treatment significantly attenuated the hypertrophy in G4H
-/-
 
mice, while MnTBAP treatment did not. Our results are similar to a previous study done 
by Ritchie et al., who found that tempol treatment attenuated hypertrophy by decreasing 
heart body weight ratio, β-myosin heavy chain as well as B-type natriuretic peptide 




Enzymes Used in the Glutathione Cycle  
Preliminary work done in our laboratory found greater GSSG and lower 
GSH:GSSG in hearts of G4H
-/-
 mice. Therefore in the present study Gpx and Gsr were 
measured at both the protein and mRNA level since both are involved in glutathione 
reduction and oxidation. While we hypothesized that G4H
-/-
 mice would have higher 
levels of Gpx, our data was inconclusive since the untreated G4H
-/-
 mice used in the 
tempol study had lower Gpx, while untreated G4H
-/-





showed no change in Gpx. It is possible that the different sample size used in both 
studies may have led to these conflicting results. Regardless of whether Gpx was 
similar or lower in G4H
-/-
 mice vs. controls, neither result supports our hypothesis that 
Gpx was greater in G4H
-/-
 mice. Also in contrast to our hypothesis was the fact that 
MnTBAP treatment did not lead to any reduction in Gpx4 protein levels. Therefore it 
appears that the reduction of GSSG in MnTBAP treated G4H
-/-
 mice observed in 
previous studies is not associated to a reduction in Gpx4. We speculate that elevated 
levels of other isoforms of Gpx, such as Gpx1, Gpx2, Gpx3 
[40]
, as well as other 
enzyme, such as glutaredoxin 
[41]
, contributed to generate GSSG. To support this point, 
we did find that Gpx1 mRNA level was increased in the cohort of G4H
-/-
 mice used in 
the tempol study. Unfortunately, we did not find different Gpx1 mRNA in another 
cohort, possibly due to the limited sample size used in the MnTBAP study. Also in 
contrast to our hypothesis, cardiac Gsr expression and protein levels were similar 
between control and G4H
-/-
 mice. Furthermore, MnTBAP had no effect on either Gsr 
expression of control and G4H
-/-
 mice. Taken together, our present data indicate that the 
reduction of GSSG after MnTBAP treatment in our previous study may result from an 
unknown mechanism, such as involvement of other Gpx or Gsr isoforms that were not 
measured in this study. 
Tempol did not change Gpx in G4H
-/- 
mice, which support the hypothesis. 
Although Gsr was reduced compared to vehicle treated G4H
-/-





this target were shown between control and G4H
-/-
 after tempol treatment. This result is 
in line with similar GSSG concentration among tempol treated groups found in 
previous study. Therefore, it is likely that Gsr may not be a critical modulator of 
hypertrophy. 
Compared to western blots, gene expression of Gpx and Gsr after tempol treatment 
demonstrated an inconsistent and more complicated pattern. We examined both Gpx1 
and Gpx4. Gpx4 is the only major antioxidant enzyme known to directly reduce 
phospholipid hydroperoxides within membranes and lipoproteins.
 [42]
 Gpx1 is the most 
abundant, classical isoenzyme in the cytoplasm of nearly all mammalian tissues. In 
contrast to western blot assay to determine protein levels of Gpx4, we found that 
tempol raised Gpx4 in control mice and lowered it in G4H
-/-
 mice. These results 
indicated that an unknown transcriptional event may be resulting in consistent amounts 
of protein being produced in spite of changes in mRNA levels.  
Txn2 is a mitochondria-specific member of the thioredoxin superfamily. Mice 
with a cardiac-specific deletion of Txn2 by the loxP-Cre system developed a severe 
phenotype of hypertrophic cardiomyopathy 
[43] 
and overexpression of Txn2 attenuated 
ANG II induced hypertrophy. 
[36] 
Based on those studies, Txn2 was expected as an 
important antioxidant to fight against hypertrophy. However, in our study the mRNA 
level of Txn2 in untreated G4H
-/-
 mice was similar to controls. A previous study by 







, which is in line with our result. They also found that Tnx2 
was increased in cardiac specific GLUT4 deleted mice after tempol treatment.
 [4]
 In 
contrast, we found that tempol did not affect Txn2 mRNA level in G4H
-/-
 mice which 
indicates that attenuation of hypertrophy by tempol may be independent of Txn2. Our 
finding stands in contrast to previous studies that report Txn2 is tightly correlated to 
hypertrophy. However, since our study measured only Txn2 mRNA level, the true 
status of the actual levels of target Txn protein in the heart remains unknown. 
 
Glycogen Synthase Kinase Pathway 
GSK3β is known as a negative regulator of cardiac hypertrophy. Increased cellular 
activity of GSK3β  produced by overexpression inhibits many aspects of cardiac 
hypertrophy, including increases in the rate of protein synthesis and hypertrophic gene 
expression.
 [44-48]
 Activation of the hypertrophic program by stimulation of β-adrenergic 
receptors, Gq-coupled receptors, and Fas receptors leads to inactivation of endogenous 
GSK3β via phosphorylation of Ser9, predominantly through the PI3K/Akt pathway. [45-49] 
We hypothesized that alterations in GSK may offer an alternative mechanism to explain 
the attenuation of hypertrophy following tempol treatment. However, our hypothesis was 
not supported since there was no difference in GSK3β phosphorylation between control 
and G4H
-/-
 mice. Furthermore, treatment with either tempol or MnTBAP did not result in 





who reported that tempol treatment markedly upregulated expression of GSK3β mRNA 
in an alternative model of cardiac specific GLUT4 deleted mice. But both the Ritchie’s et 
al. and our study did not found significant difference in GSK3β between control and 
G4H
-/-
 mice. Therefore, the attenuation of cardiac hypertrophy in G4H
-/-
 mice after 
tempol treatment may not result from modulation of GSK3β. However, protein change 
was not measured by Richtie et al., so it is unknown if the changes in mRNA actually led 
to relevant changes in protein.  
The limitation of the present study is the small sample size used in the MnTBAP 
study. This may have contributed to the fact that data for Gpx were inconsistent among 
vehicle treated mice between the MnTBAP cohort and the tempol cohort. It also led to 
low statistic power to detect significance of GSK3β phosphorylation among vehicle 
treated mice. Another possible explanation for inconsistent Gpx data among these groups 
is the different vehicle treatment used between tempol and MnTBAP treatments. For 
example, compared with using drinking water as a vehicle during the tempol study, the 
vehicle saline injection used in the MnTBAP study may have caused some stress related 
effects that invalidate a comparison of vehicle treated controls between these two distinct 
cohorts. Other than the possibilities mentioned above, different parts of heart contained in 
the tissue pieces for western blot and quantification of mRNA probably led to 





In conclusion, the major findings of the present study are that a) the reduction of 
hypertrophy after tempol treatment is not related to changes in GSK3β activity or Txn2 
expression, b) the reduction in GSSG concentrations observed in our previous studies 
after MnTBAP treatment is not associated to changes in glutathione oxidation and 
reduction cycle enzymes, Gpx and Gsr. Therefore, we speculate that the attenuation of 
cardiac hypertrophy in G4H
-/-
 mice after tempol treatment may in fact result from 
mechanisms unrelated to oxidative stress. Further studies are needed to elucidate the 
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